Semaglutide vs Tirzepatide vs Retatrutide: The Complete GLP-1 Comparison (2026)

The GLP-1 Landscape in 2026#

Three molecules now dominate conversations about pharmacological weight management: semaglutide, tirzepatide, and retatrutide. Each represents a successive generation of incretin-based therapy — from single receptor activation to dual, to triple — and the differences in their pharmacology translate directly into differences in efficacy, tolerability, and clinical fit.

This guide provides a unified, three-way analysis rather than the typical pairwise comparison. The goal is a decision framework: which agent fits which patient profile, based on the available evidence as of early 2026.

---

Receptor Pharmacology: What Each Drug Actually Does#

Understanding why these drugs differ requires a brief tour of their receptor targets.

Semaglutide — GLP-1 single agonist Semaglutide is a modified GLP-1 (glucagon-like peptide-1) analog with ~94% sequence homology to native GLP-1, engineered for once-weekly dosing via a C-18 fatty diacid linker that enables albumin binding. It activates the GLP-1 receptor in pancreatic beta cells (stimulating glucose-dependent insulin secretion), hypothalamic neurons (suppressing appetite), and gastric tissue (slowing emptying). FDA-approved as Ozempic (T2D) and Wegovy (obesity, 2.4 mg weekly).

Tirzepatide — dual GIP/GLP-1 agonist Tirzepatide is a synthetic 39-amino-acid peptide that functions as a balanced co-agonist at both GIP and GLP-1 receptors. The GIP receptor component independently potentiates glucose-stimulated insulin secretion, reduces glucagon, and — critically — appears to suppress nausea pathways that pure GLP-1 agonism activates. This may explain why tirzepatide achieves greater weight loss at doses with comparable or better GI tolerability compared to semaglutide. FDA-approved as Mounjaro (T2D) and Zepbound (obesity).

Retatrutide — triple GIP/GLP-1/glucagon agonist Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 platform. This third agonism drives increased energy expenditure (thermogenesis), enhanced hepatic fat oxidation, and reduced liver fat accumulation — effects not reliably achievable with dual agonists. The trade-off is that glucagon receptor activation raises concerns about cardiovascular stress at higher doses. As of early 2026, retatrutide is in Phase 3 TRIUMPH trials and is not FDA-approved.

---

Head-to-Head Efficacy: Trial Data Compared#

STEP Trials (Semaglutide)#

The STEP program enrolled over 4,500 adults with obesity (BMI ≥30 or ≥27 with comorbidity). In STEP 1 (N=1,961, 68 weeks), semaglutide 2.4 mg weekly produced a mean weight reduction of 14.9% versus 2.4% for placebo. STEP 2 confirmed benefit in T2D patients (~9.6% weight loss). STEP 4 demonstrated rebound weight gain upon discontinuation, underscoring the chronicity of treatment needed.

SURMOUNT Trials (Tirzepatide)#

SURMOUNT-1 (N=2,539, 72 weeks) showed tirzepatide at 15 mg weekly achieved 22.5% mean weight loss (vs 2.4% placebo). The 10 mg dose achieved 21.4% and the 5 mg dose 16.0%. SURMOUNT-2 replicated these findings in T2D patients (~15.7% at 15 mg). The pivotal SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg in T2D: tirzepatide 15 mg reduced HbA1c by 2.58% vs 1.86% for semaglutide, and weight by 12.4 kg vs 6.2 kg — roughly double the weight reduction.

TRIUMPH Trials (Retatrutide)#

Retatrutide's Phase 2 trial (N=338, 48 weeks) was published in the New England Journal of Medicine in 2023. At the highest dose (12 mg weekly), retatrutide produced mean weight loss of 24.2% — the largest body weight reduction ever reported in a Phase 2 obesity trial at that time. The Phase 3 TRIUMPH-1 and TRIUMPH-2 trials are currently underway with results expected in 2026–2027.

---

Side Effect Profiles Compared#

All three drugs share a GLP-1–mediated core side effect profile: nausea, vomiting, diarrhea, and constipation — predominantly during dose escalation. The important distinctions:

Nausea and vomiting: Semaglutide shows the highest rates; tirzepatide's GIP co-agonism appears to reduce nausea incidence at weight-loss–equivalent doses. Retatrutide's Phase 2 data show nausea rates comparable to tirzepatide, but doses in Phase 3 are higher and data are pending.

Gallbladder disease: Rapid weight loss with any of these agents increases cholelithiasis risk. Semaglutide's long-term CVOT data (SELECT trial, 2023) showed elevated gallbladder events. Tirzepatide shows similar signals. Retatrutide data are immature.

Cardiovascular: The SELECT trial (N=17,604) established semaglutide's cardiovascular benefit — 20% reduction in MACE in high-risk cardiovascular patients with obesity but without diabetes. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT/SURMOUNT-MMO) is ongoing. Retatrutide's glucagon agonism component raises theoretical cardiovascular concern during rapid escalation.

Muscle mass: A recognized concern with all potent weight-loss agents is lean mass loss alongside fat mass. Retatrutide's glucagon agonism may theoretically worsen muscle catabolism at higher doses, though Phase 2 body composition data did not confirm this definitively.

Pancreatitis: Class risk for all GLP-1–containing agents; incidence is low but requires monitoring.

---

Cost, Access, and Practical Considerations#

Semaglutide (Wegovy) lists at approximately $1,300–$1,500/month without insurance in the US. Tirzepatide (Zepbound) entered the market at a comparable price point but Eli Lilly has offered savings programs. Retatrutide is not yet commercially available.

Compounded semaglutide and tirzepatide became widely accessible in 2023–2024 when both were on the FDA drug shortage list. As of early 2026, the shortage status of branded products has evolved and compound availability is more restricted — physicians and patients should verify current FDA guidance.

---

Which GLP-1 Is Right for Which Patient?#

Choose semaglutide when:

• Long-term cardiovascular outcome data are essential (SELECT trial evidence)
• The patient has established cardiovascular disease (semaglutide has the strongest CVOT data set)
• Cost/insurance formulary favors Ozempic or Wegovy
• Oral administration (Rybelsus) is preferred over injection

Choose tirzepatide when:

• Maximum weight loss within the approved drug class is the priority
• GI tolerability has been a barrier with semaglutide
• Concomitant lipid improvement is a therapeutic goal (tirzepatide shows stronger TG/HDL effects via GIP)
• T2D management is the primary indication

Consider retatrutide (when approved) when:

• Prior dual agonist therapy was insufficient
• Hepatic steatosis / MASH is a co-existing condition (glucagon receptor agonism directly targets liver fat)
• The patient can be monitored in a clinical setting during dose titration

---

Conclusion#

Semaglutide, tirzepatide, and retatrutide are not interchangeable — they represent distinct pharmacological generations with meaningfully different efficacy ceilings, tolerability profiles, and evidence bases. Semaglutide remains the most evidence-rich choice, especially for cardiovascular risk reduction. Tirzepatide is currently the highest-efficacy approved agent, with a favorable tolerability profile. Retatrutide's Phase 2 data are remarkable, but Phase 3 results and regulatory approval are still outstanding.

For most patients starting GLP-1 therapy today, tirzepatide offers the best balance of proven efficacy and regulatory standing. Semaglutide remains appropriate when CVOT data or specific access circumstances favor it. Retatrutide warrants attention for future use — particularly in patients with substantial hepatic or severe obesity targets — once Phase 3 safety data mature.